Galderma Targets Accelerated Expansion as U.S. Wrinkle Treatment Filing Approaches
Zurich, Thursday, 19 November 2026.
Galderma signaled sustained growth through 2027, driven by international expansion, selective acquisitions, and plans to file its Botox competitor, Relfydess, in the United States in early 2027.
Galderma’s Growth Momentum and Strategic Vision
On Thursday, 19 November 2026, Galderma Group AG (SIX: GALD) convened an investor meeting in Zurich with Jefferies, where Chief Executive Officer Flemming Ørnskov outlined a bullish outlook for the Swiss dermatology company’s expansion through 2027 [1][2][4][5]. The optimism centered on a broad-based commercial strategy leveraging both dermatology and aesthetics portfolios, which have demonstrated sustained demand in global premium skincare and injectable treatments [1][2][4][5]. Analysts from Jefferies characterized 2026 as a year of accelerated growth, driven by diversified momentum across product lines and geographic markets [1][2][4][5]. Looking ahead, 2027 is poised to accelerate further, with new product launches and geographic expansion expected to unlock significant growth potential, particularly through the deployment of existing products into untapped markets [1][2][4][5].
Relfydess Filing and Regulatory Milestones
A key near-term catalyst for Galderma is the anticipated filing of Relfydess, an injectable aesthetic treatment designed to temporarily smooth facial wrinkles by temporarily blocking nerve signals responsible for muscle contraction—mechanistically similar to Botox [1][2][4][5]. Jefferies confirmed that Galderma’s management remains on track to submit the U.S. application for Relfydess in the first quarter of 2027, marking a pivotal regulatory step for the company’s aesthetics portfolio [1][2][4][5]. The treatment’s potential approval could significantly bolster Galderma’s competitive positioning in the injectable aesthetics market, a segment the company continues to view with strong enthusiasm [1][2][4][5].
Financial Leadership Transition and Shareholder Confidence
Galderma’s leadership transition in the Chief Financial Officer (CFO) role has been evaluated by Jefferies as controlled rather than disruptive [1][2][4][5]. The departure of Luigi La Corte in early November 2026, after only six months in the position, prompted management to announce plans to appoint a successor in the first half of 2027 [1][2][4][5]. Despite this transition, Jefferies maintained its ‘buy’ recommendation on Galderma’s stock, setting a price target of 220 Swiss francs (CHF), which implies an 17.584 upside potential based on the closing price of 187.10 CHF on 19 November 2026 [1][2][4][5].
M&A Appetite and Long-Term Strategic Outlook
Galderma’s strategic focus remains oriented toward selective mergers and acquisitions (M&A), with a particular emphasis on prescription drugs (Rx) and injectable aesthetics [1][2][4][5]. The company continues to evaluate opportunities within the Rx segment while maintaining strong interest in aesthetics, especially injectable products [1][2][4][5]. This M&A strategy is expected to complement organic growth initiatives, further solidifying Galderma’s position in both dermatology and aesthetic medicine. As analysts note, the company’s diversified product pipeline and geographic reach position it well to capitalize on evolving market dynamics in premium skincare and aesthetic treatments [1][2][4][5].
Sources
- ca.marketscreener.com
- www.boursorama.com
- nl.marketscreener.com
- ch.marketscreener.com
- www.six-group.com